Skip to content

Alkermes ALKS Research And Development — Revenue Remaining Performance Obligation

Discontinued — last reported Q3 '18

Similar metrics at other companies

Blackrock logo
BLKInvestment Advice — Revenue Remaining Performance Obligation
$1.11B-20.0%
Blackrock logo
BLKTechnology Services And Subscription Revenue — Revenue Remaining Performance Obligation
$509M+6.0%
Nasdaq, Inc. logo
NDAQRegulatory Technology — Revenue, remaining performance obligation
$1.02B+27.1%
BridgeBio Pharma logo
BBIOResearch and Development Services — Deferred revenue, net of current portion
$1.9M
Berkshire Hathaway logo
BRK.AOther Sales And Service Contracts — Revenue Remaining Performance Obligation
$14.48B+80.9%
BridgeBio Pharma logo
BBIOResearch and Development Services — Deferred revenue, current portion
$800K

Other financials

Income statement

See full
Revenue$392.9M+28.2%
Gross profit$331.3M+28.8%
Operating income-$48.3M-450%
Net income-$66.5M-396%
EPS (diluted)-$0.40-408%

Balance sheet

See full
Cash & equivalents$351.6M-12.1%
Total debt$1.6B+2,034%
Total equity$1.8B+15.9%
Total assets$4.3B+105%

Cash flow

See full
Operating cash flow-$165.7M-268%
CapEx$4.1M-59.5%
Free cash flow-$169.8M-291%

Valuation

See full
Market cap$7.5B+9.7%
Enterprise value$8.73B+41.2%
P/E49.1×+29.7×
P/S4.8×+0.3×

Profitability

See full
Gross margin86.6%+2.2pp
Operating margin12.3%-13.6pp
Net margin9.8%-13.5pp
FCF margin14.2%-17.6pp

Returns & leverage

See full
Return on equity9.4%-16.1pp
Debt / equity0.9×+0.9×
Current ratio2.3×-1.1×

Where this comes from

Reported directly by Alkermes in its filing.

Tagged under the XBRL concept us-gaap:RevenueRemainingPerformanceObligation.

The official record: Alkermes’s 10-Q, filed October 23, 2018, on SEC EDGAR. View the filing →

Questions, answered.

What does research and development — revenue remaining performance obligation mean?
This metric represents the total transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. It provides visibility into future revenue that is contractually secured from existing R&D partnerships. This is a critical forward-looking indicator of the stability and longevity of the company's research-based revenue streams.